MAG Antibody Testing
Test in Focus
Mayo Clinic Laboratories now offers an in-house ELISA assay to test for the presence of antibodies against myelin-associated glycoprotein (MAG) antibodies. In this episode of the “Answers From the Lab” podcast, John Mills, Ph.D., discusses how the semi-quantitative, calibrated assay uses unique, human MAG antigen that improves on earlier assays for detection of MAG antibodies. These antibodies are important biomarkers of the rare, hard-to-treat distal acquired demyelinating symmetric neuropathy (DADS).
Although DADS can theoretically be diagnosed through clinical presentation and nerve conduction studies, those finding are less straightforward in practice, says Dr. Mills. “They are complex and heterogenous, and this partly explains why there tends to be a two- to three-year lag in these patients from the time they present with the neuropathy until they formally are diagnosed with DADs or MAG neuropathy.”
Listen to learn more about how incorporating MAG antibody testing into the diagnostic workup can help guide clinicians to the correct diagnosis earlier, equipping them with confidence about disease presence to guide treatment decisions.
Note: Podcasts will not playback on Internet Explorer. Please use an alternative web browser, or listen from your mobile device on a preferred listening app.
Evaluating peripheral neuropathy and paraproteinemic neuropathy.
Melissa Snyder, Ph.D., explains how Mayo Clinic Laboratories' EDN panel improves the evaluation of certain patients with asthma and autoimmune digestive disorders. EDN is the first laboratory test that provides a marker of eosinophil-derived neurotoxins.
Gang Zheng, M.D., Ph.D., and Aaron Mansfield, M.D., describe Mayo Clinic Laboratories’ liquid biopsy, which analyzes blood samples for genetic information to guide cancer treatment. The circulating tumor DNA assay uses next generation sequencing and complements the laboratory's cell-based cancer testing.
Linda Hasadsri, M.D., Ph.D., explains carrier screening at Mayo Clinic Laboratories. Using targeted genotyping, our three focused panels evaluate genes associated with cystic fibrosis, spinal muscular atrophy, and hemoglobinopathies, to provide clear answers on reproductive risks and to guide decision-making.